Biotech is back. Here's why these rallying stocks belong in your portfolio now.

The biotech sector is experiencing a robust rebound, with the SPDR S&P Biotech ETF (XBI) up 25% year-to-date, significantly outperforming the S&P 500. This resurgence is attributed to several fundamental tailwinds, including positive drug trial results now being rewarded by the market, increased M&A activity driven by major pharmaceutical companies' patent expirations, and successful new drug launches. Furthermore, a more favorable macroeconomic environment with falling interest rates, easing regulatory uncertainties, reduced tariff risks, and a recent "cleansing" of weaker companies are collectively fostering sustained investor confidence and are expected to drive continued sector outperformance.

Analysis

The biotech sector is experiencing a significant resurgence, with the SPDR S&P Biotech ETF (XBI) up 25% year-to-date through October 31, outperforming the S&P 500 by 9 percentage points. This rebound follows a four-year slump and is characterized by improved investor sentiment and fund flows, suggesting sustained momentum. Analysts like Karl Thiel and Paul Matteis confirm a bullish outlook, citing credible and sustainable fundamental drivers.

Positive drug trial results are now being rewarded by the market, exemplified by UniQure (QURE) soaring over 350% and Praxis Precision Medicines (PRAX) gaining more than 230% post-data. Concurrently, M&A activity is accelerating, driven by large pharmaceutical companies facing patent expirations, leading to significant gains for targets like Regulus Therapeutics (RGLS) (up 120%) and 89bio (ETNB) (up 85%). This M&A trend is expected to continue, re-rating biotech valuations.

Falling U.S. interest rates are reducing funding costs for cash-intensive biotech firms and increasing the net present value of companies with distant earnings, making "nonearners" more attractive. Furthermore, easing regulatory uncertainties, including a more predictable FDA approval process and reduced drug-price control risks, contribute to a more favorable operating environment. The sector has also undergone a "cleansing" of weaker companies post-COVID frenzy, strengthening its overall health.

Key Decisions for Investors

• Investors should consider increasing exposure to the biotech sector, given the strong fundamental tailwinds, improving sentiment, and historical outperformance of the XBI ETF.
• Focus on companies with upcoming or recent positive drug trial data and those identified as potential M&A targets, as these factors are currently driving significant share price appreciation.
• Monitor interest rate trends and regulatory developments, as continued stability or improvement in these areas will be crucial for sustaining the sector's positive trajectory.
• Conduct thorough due diligence on individual biotech names, particularly those with successful commercial launches or strong pipelines, while acknowledging the sector's inherent volatility.